Epizyme Raises $32 Million

Epizyme Inc., a Cambridge, Mass.-based biopharma company focused on the application of epigenetics, has raised $32 million in Series B funding. Bay City Capital led the round, and was joined by Amgen Ventures, Astellas Venture Partners and return backers MPM Capital and Kleiner Perkins Caufield and Byers. The company previously raised $14 million.

North AmericaUSBriefs